What is HC Wainwright’s Forecast for REGENXBIO Q3 Earnings?

REGENXBIO Inc. (NASDAQ:RGNX) – Equities researchers at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of REGENXBIO in a note issued to investors on Tuesday, February 10th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.61) per share for the quarter, down from their prior estimate of ($0.22). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($3.63) EPS.

A number of other brokerages have also weighed in on RGNX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Leerink Partners upped their target price on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. UBS Group reaffirmed an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a research note on Tuesday. Barclays began coverage on REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective on the stock. Finally, Morgan Stanley cut their price objective on REGENXBIO from $25.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, REGENXBIO currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.80.

REGENXBIO Price Performance

RGNX opened at $7.99 on Thursday. The stock’s 50 day moving average price is $13.08 and its 200 day moving average price is $11.38. The stock has a market cap of $404.45 million, a P/E ratio of -2.30 and a beta of 1.05. REGENXBIO has a 12 month low of $5.03 and a 12 month high of $16.19.

Hedge Funds Weigh In On REGENXBIO

A number of hedge funds have recently added to or reduced their stakes in RGNX. State of Alaska Department of Revenue bought a new position in REGENXBIO during the third quarter valued at about $25,000. Aquatic Capital Management LLC acquired a new position in shares of REGENXBIO during the 3rd quarter valued at about $37,000. Jones Financial Companies Lllp lifted its holdings in REGENXBIO by 44.4% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,270 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in REGENXBIO by 754.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the period. Finally, Captrust Financial Advisors acquired a new position in REGENXBIO during the second quarter valued at approximately $85,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.